Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …

Somatic mosaicism, the occurrence of multiple genetically distinct cell clones within the
same tissue, is an evitable consequence of human aging. The hematopoietic system is no …

Preclinical models have shown that blocking PD-1/PD-L1 pathways enhances antileukemic
responses. Azacitidine upregulates PD-1 and IFNγ signaling. We therefore conducted this …

Background Age-related clonal hematopoiesis of indeterminate potential (CHIP), defined as
clonally expanded leukemogenic sequence variations (particularly in DNMT3A, TET2 …

Patient outcome in primary myelofibrosis (PMF) is significantly influenced by karyotype. We
studied 879 PMF patients to determine the individual and combinatorial prognostic …

Purpose Recurrently mutated genes in myelodysplastic syndrome (MDS) are pathogenic
drivers and powerfully associated with clinical phenotype and prognosis. Whether these …

Recurrent somatic ASXL1 mutations occur in patients with myelodysplastic syndrome,
myeloproliferative neoplasms, and acute myeloid leukemia, and are associated with …

Myelodysplasia is a diagnostic feature of myelodysplastic syndromes (MDSs) but is also
found in other myeloid neoplasms. Its molecular basis has been recently elucidated by …

Mutations in genes of the splicing machinery have been described recently in
myelodysplastic syndromes (MDS). In the present study, we examined a cohort of 193 MDS …

Somatic Addition of Sex Combs Like 1 (ASXL1) mutations occur in 10–30% of patients with
myeloid malignancies, most commonly in myelodysplastic syndromes (MDSs), and are …